Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

New phosphatidylinositol 3-kinase inhibitors for cancer.

Expert opinion on investigational drugs - 1 Apr 2011

Bowles Daniel W, Jimeno Antonio

Abstract excerpt

INTRODUCTION: Cancer treatment is moving away from conventional cytotoxic drugs and towards agents that target specific proteins important to cancer development or survival. The PI3K signaling axis is an important pathway involved in myriad human malignancies. Inhibition of this axis is a promising therapeutic approach for several cancers. AREAS COVERED: This article reviews current literature and recent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drugs, Investigational

Share to Enzyme Inhibitors

Share to Phosphatidylinositol 3-Kinase

Share to Phosphoinositide-3 Kinase Inhibitors

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 21395485
DOI: 10.1517/13543784.2011.562192

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

New phosphatidylinositol 3-kinase inhibitors for cancer.PMID 21395485Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

PI3K inhibitors for cancer treatment: where do we stand?Semantic proximity Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.Semantic proximity Read ↗

Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directionsSemantic proximity Read ↗

Targeting PI3K in Cancer: Any Good News?Semantic proximity Read ↗

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapySemantic proximity Read ↗

Inhibition of the PI3K Pathway: Hope We Can Believe in?Semantic proximity Read ↗

Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).Semantic proximity Read ↗

Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.Semantic proximity Read ↗

Challenges in the clinical development of PI3K inhibitors.Semantic proximity Read ↗

Advances in subunits of PI3K class I in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.